

12.05.2009 - 18:38 Uhr

EANS-Adhoc: LifeWatch announces the appointments of Dr. Andrea Natale and Dr. John F. Beshai to its Medical Advisory Board

Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich.

Forschung/Entwicklung/Medical Advisory Board

12.05.2009

Neuhausen am Rheinfall / Switzerland and Chicago / USA, May 12, 2009 - Card Guard AG's (SIX Swiss Exchange: CARDG) American subsidiary LifeWatch Services, Inc., the leader in the provision of wireless telemedicine services in the U.S., announced that Andrea Natale, M.D., and John F. Beshai, M.D., have joined the Company's Medical Advisory Board (MAB). The LifeWatch MAB is comprised of renowned physicians and researchers in the fields of cardiology and electro-physiology. In their capacity as MAB members Dr. Natale and Dr. Beshai will provide guidance and support in the development of LifeWatch's clinical strategy and patient care programs for Atrial Fibrillation and Syncope.

"We are extremely pleased and excited to have such esteemed colleagues become part of LifeWatch's Medical Advisory board", stated Harry Kopelman, M.D., LifeWatch Medical Advisory Board Chairman. "Dr. Beshai and Dr. Natale will accelerate our efforts and deepen our clinical expertise", he added.

Dr. Andrea Natale is a world renowned electrophysiologist and was the first electrophysiologist in the U.S. to perform percutaneous epicardial radiofrequency ablation, which is a treatment for people who fail conventional ablation. Dr. Natale has served as director of the electrophysiology laboratory at Duke University, director of the electrophysiology program at the University of Kentucky, Lexington, and as a professor at prestigious universities, including Duke University and Stanford University. In addition to serving on the editorial boards of numerous medical journals, he is editor-in-chief of the Journal of Atrial Fibrillation. Dr. Natale graduated summa cum laude from the Medical School of the University of Florence, Italy, and summa cum laude from the Catholic University School of Cardiology in Rome, Italy. He received his clinical training in cardiology at Methodist Hospital, Baylor College in Houston and at the University of Western Ontario in London, Ontario, Canada. After completing a clinical fellowship in cardiology (electrophysiology) at the University of Western Ontario in 1991, he further trained in cardiology (electrophysiology) at the University of Wisconsin, Sinai Samaritan Medical Center in Milwaukee.

Dr. John Beshai serves as the Director of Pacemaker and Defibrillator Services at the University of Chicago, and is an Assistant Professor of Medicine at the University of Chicago's Pritzker School of Medicine. Dr. Beshai has served as an Assistant Professor of Medicine at the Emory University School of Medicine. He completed his fellowships in Clinical Cardiac Electrophysiology and Cardiovascular Medicine from the Hospital of the University of Pennsylvania, and has a fellowship in Cardiovascular Medicine from the New England Medical

Center at Tufts University School of Medicine in Boston. Dr. Beshai completed his undergraduate degree at The Ohio State University followed by his Medical Degree at St. George's University in 1996. He served as National P.I. and Steering Committee Chairman for the Resynchronization Therapy in Patients with Heart Failure and Narrow QRS (RETHINQ). In addition, he serves as a peer reviewer for numerous journals including JCE, HRS, and AJC.

LifeWatch Medical Advisory Board:

Harry Kopelman, M.D. - Atlanta, GA

Dr. Kopelman is Co-Director of Electrophysiology Research and affiliate Scientist at the Piedmont Heart Institute where he has played a central role in the program's development and ongoing clinical and pre-clinical research.

John F. Beshai, M.D., F.A.C.C., F.H.R.S. - Chicago, IL

Dr. John Beshai serves as the Director of Pacemaker and Defibrillator Services at the University of Chicago, and is an Assistant Professor of Medicine at the University of Chicago's Pritzker School of Medicine

Alan Kadish, M.D., F.A.C.C., F.H.R.S. - Evanston, IL

Dr. Kadish is a fellow of both the American College of Cardiology and the American Heart Association, and sits on the editorial board or is an Editorial Consultant for more than a dozen cardiology journals. Dr. Kadish serves as Senior Associate Chief of Cardiology at Northwestern Memorial Hospital.

Andrea Natale, M.D., F.A.C.C., F.H.R.S. - San Francisco, CA

Dr. Natale is the Senior Medical Director of the California Pacific Medical Center for Atrial Fibrillation and Arrhythmia Program in San Francisco, CA. In addition to serving on the editorial boards of numerous medical journals, he is editor-in-chief of the Journal of Atrial Fibrillation. Biography of Dr. Andrea Natale

James Reiffel, M.D. F.A.C.C., F.H.R.S. - NYC, NY

Dr. Reiffel is a Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons; Attending Physician, Columbia Presbyterian Medical Center Campus.

Steve Prater, M.D. - Atlanta, GA

Dr. Prater is a board certified cardiologist and electrophysiologist. Dr. Prater completed his Electrophysiology fellowship at Loyola University of Chicago, and is currently a practicing Electrophysiologist at the Piedmont Heart Institute.

About Card Guard AG

Card Guard AG, headquartered in Neuhausen am Rheinfall, Switzerland, is a leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless cardiac monitoring services. Card Guard services treat high-risk and chronically ill patients, health conscious consumers and wellness programs. Card Guard has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. Card Guard AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and LifeWatch Technologies Inc., a US-based manufacturer of telecardiology products. www.cardguard.com

About LifeWatch Corp.

LifeWatch is a wholly owned subsidiary of Card Guard AG, a leading healthcare technology and solutions provider listed on SIX Swiss Stock Exchange (CARDG). LifeWatch Corp., through its operating subsidiaries LifeWatch Services, Inc. and LifeWatch Technologies, Inc. (Instromedix) is an independent provider of ambulatory cardiac monitoring services and a manufacturer and distributor of ambulatory cardiac and vital signs monitoring devices in the United States. Its current services are used by physicians primarily to monitor patients who are suspected of having heart rhythm disorders, or cardiac arrhythmias, and its products are used by itself and by others in connection with providing cardiac monitoring services. For more information, visit: www.lifewatch.com.

Upcoming Card Guard Events

18 May 2009 Analysts' and Media conference Results Q1 2009

26 May 2009 Annual Shareholder Meeting of Card Guard AG in Zurich

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. Card Guard AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to Card Guard AG at the time of the issue of this press release. Card Guard AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF CARD GUARD AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF CARD GUARD AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF CARD GUARD AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM CARD GUARD AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.

Rückfragehinweis:

Kobi Ben Efraim
Chief Financial Officer
Tel +41 52 632 00 50 | Fax +41 52 632 00 51

Email kobibe@cardguard.com

Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12
Email cardguard@sensus.ch

Branche: Gesundheitsdienste
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market (Freiverkehr) / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / Freiverkehr

Diese Meldung kann unter <https://www.presseportal.ch/de/pm/100017242/100583041> abgerufen werden.